BioCryst Pharmaceuticals (NASDAQ:BCRX) Trading Up 5.6% – What’s Next?

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) traded up 5.6% on Monday . The stock traded as high as $8.09 and last traded at $8.07. 2,011,286 shares changed hands during mid-day trading, a decline of 20% from the average session volume of 2,528,297 shares. The stock had previously closed at $7.64.

Analysts Set New Price Targets

BCRX has been the topic of several research reports. Barclays boosted their price target on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an “equal weight” rating in a research note on Tuesday, November 5th. Evercore ISI upped their target price on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an “outperform” rating in a research note on Monday, January 13th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $10.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 5th. Finally, Needham & Company LLC increased their price objective on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “buy” rating in a research note on Monday, January 13th. One analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $15.17.

BioCryst Pharmaceuticals Trading Up 1.1 %

The firm has a market cap of $1.66 billion, a P/E ratio of -13.15 and a beta of 1.76. The company’s fifty day moving average price is $7.62 and its two-hundred day moving average price is $7.68.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share for the quarter, hitting the consensus estimate of ($0.07). The firm had revenue of $117.10 million for the quarter, compared to the consensus estimate of $113.99 million. During the same period in the prior year, the company posted ($0.19) earnings per share. BioCryst Pharmaceuticals’s quarterly revenue was up 35.1% compared to the same quarter last year. On average, analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.38 EPS for the current fiscal year.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. lifted its position in BioCryst Pharmaceuticals by 21.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company’s stock worth $57,000 after buying an additional 1,322 shares in the last quarter. Xponance Inc. raised its stake in shares of BioCryst Pharmaceuticals by 13.1% in the second quarter. Xponance Inc. now owns 12,980 shares of the biotechnology company’s stock worth $80,000 after acquiring an additional 1,505 shares during the last quarter. Captrust Financial Advisors lifted its position in shares of BioCryst Pharmaceuticals by 19.4% during the third quarter. Captrust Financial Advisors now owns 16,274 shares of the biotechnology company’s stock worth $124,000 after purchasing an additional 2,644 shares in the last quarter. Creative Planning grew its stake in shares of BioCryst Pharmaceuticals by 5.9% during the third quarter. Creative Planning now owns 49,347 shares of the biotechnology company’s stock valued at $375,000 after purchasing an additional 2,734 shares during the last quarter. Finally, SkyView Investment Advisors LLC increased its holdings in shares of BioCryst Pharmaceuticals by 30.0% in the third quarter. SkyView Investment Advisors LLC now owns 13,000 shares of the biotechnology company’s stock valued at $99,000 after purchasing an additional 3,000 shares in the last quarter. Institutional investors and hedge funds own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.